EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Rumona Dickson, Angela Boland, Rui Duarte, Eleanor Kotas, Nerys Woolacott, Robert Hodgson, Rob Riemsma, Sabine Grimm, Bram Ramaekers, Manuela Joore, Nasuh Buyukkaramikli, Eva Kaltenthaler, Matt Stevenson, Abdullah Pandor, Steve Edwards, Martin Hoyle, Jonathan Shepherd, Xavier Armoiry, Miriam Brazzelli

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)429-432
Number of pages4
JournalApplied Health Economics and Health Policy
Volume16
Issue number4
DOIs
Publication statusPublished - 1 Aug 2018

Cite this

Dickson, R., Boland, A., Duarte, R., Kotas, E., Woolacott, N., Hodgson, R., Riemsma, R., Grimm, S., Ramaekers, B., Joore, M., Buyukkaramikli, N., Kaltenthaler, E., Stevenson, M., Pandor, A., Edwards, S., Hoyle, M., Shepherd, J., Armoiry, X., & Brazzelli, M. (2018). EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Applied Health Economics and Health Policy, 16(4), 429-432. https://doi.org/10.1007/s40258-018-0393-7